The global mycoplasma diagnostics market is witnessing steady expansion, driven by the increasing prevalence of mycoplasmal infections and growing demand for rapid, accurate, and cost-effective diagnostic solutions. Valued at US$ 1.0 billion in 2023, the market is projected to grow at a CAGR of 7.4% from 2024 to 2034, reaching approximately US$ 2.1 billion by the end of 2034.
Rising Prevalence of Mycoplasmal Infections
The growing incidence of mycoplasmal infections is a major factor driving market development. Mycoplasma can affect several parts of the human body, with Mycoplasma pneumoniae being a recognized cause of community-acquired pneumonia, particularly among children and young adults. The need for early identification and appropriate treatment is consequently increasing demand for reliable diagnostic testing.
Another important infection is Mycoplasma genitalium, an emerging cause of genital discharge and sexually transmitted infection. Studies from Western Europe, North America, and Australia have reported prevalence estimates ranging from 1% to 3.3% among men and 1% to 6.4% among women.
The introduction and widespread adoption of polymerase chain reaction (PCR) have significantly expanded the diagnostic landscape. DNA probes and molecular techniques targeting mycoplasmal genetic material can support detection in human and animal infections. PCR, particularly when combined with serological testing, can provide an effective approach for diagnosing Mycoplasma pneumoniae infections.
R&D of Rapid Diagnostic Tests Supports Market Growth
Research and development of rapid diagnostic technologies represents another important growth driver. Mycoplasma pneumoniae is a significant cause of community-acquired pneumonia in children, creating demand for diagnostic methods that can deliver results quickly and support timely clinical decision-making.
Nucleic acid amplification techniques are emerging as promising tools for rapid detection of Mycoplasma pneumoniae. At the same time, advances in immunochromatographic antigen assays and colloidal gold-based tests are creating additional opportunities. These methods are designed to provide rapid, sensitive, and relatively simple identification of infection.
Technological progress is also making molecular diagnostics more accessible. Reduced costs per sample, lower labor requirements, automation, and improved testing platforms have expanded the use of molecular diagnostic technologies across clinical and laboratory applications.
Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1677
Regional Outlook
North America held a leading position in the global mycoplasma diagnostics market. The region benefits from the presence of major research laboratories, established healthcare infrastructure, and increasing attention toward respiratory infections.
Europe is also witnessing increased demand for diagnostic testing amid renewed cases of Mycoplasma pneumoniae. A January 2024 study published in Eurosurveillance reported 133 PCR-positive patients at Spaarne Gasthuis in the Netherlands during 2023, with children representing a substantial share of cases.
Meanwhile, Asia Pacific is expected to register steady growth during the forecast period. Increasing respiratory tract infections, expanding healthcare infrastructure, and rising healthcare expenditure are creating favorable conditions for market development.
Competitive Landscape
The competitive landscape comprises established diagnostics, life sciences, and laboratory technology companies. Major participants include F. Hoffmann-La Roche Ltd., Agilent Technologies, Sartorius AG, Savyon Diagnostics, Takara Bio Inc., Lonza Group, Merck & Co., Inc., Charles River Laboratories International, Inc., Thermo Fisher Scientific Inc., and PromoCell GmbH.
These companies are focusing on PCR-based solutions, rapid assays, automation, and ultrasensitive technologies designed to improve detection of mycoplasma and acholeplasma contamination in cell cultures and biological products.
A notable development occurred in 2023, when Wells Bio, a subsidiary of Access Bio, announced plans to export its careGENE Pneumonia Detection Kit to help address Mycoplasma pneumoniae outbreaks in Asia and Europe.
Outlook
Overall, increasing infection prevalence, technological advances, and continued R&D in rapid diagnostic testing are expected to sustain the mycoplasma diagnostics market growth through 2034. As healthcare providers and laboratories increasingly prioritize early, sensitive, and convenient detection, innovations in molecular and immunological testing are likely to remain central to the industry's expansion.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453